MYD88 and neoplasm: Our findings, therefore, raise the possibility that ETS1 amplifies the tumor-promoting effects of these mutants by increasing their expression and, indeed, ETS1 gains are common in the ABC-DLBCL cluster 5 characterized by MYD88 and CD79A/B [4].